Royalty Pharma has announced a strategic move to acquire its external manager, RP Management, LLC, in a bid to simplify its corporate structure and enhance shareholder value. This acquisition is expected to generate significant financial benefits, including cash savings exceeding $100 million in 2026 and more than $175 million by 2030, with cumulative savings projected to surpass $1.6 billion over the next
Royalty Pharma plc (RPRX) is experiencing a rise in its stock price today, potentially influenced by recent institutional interest. Point72 DIFC Ltd disclosed a new position in Royalty Pharma, purchasing 65,861 shares valued at approximately $1.86 million. This move is part of a broader trend, as several other institutional investors and hedge funds have also modified their holdings in the company. The incr
Royalty Pharma plc's stock is experiencing an uptick in after-hours trading following a series of positive announcements. The company reported robust third-quarter growth and raised its full-year guidance for 2024. Specifically, Royalty Pharma announced a 15% increase in both Portfolio Receipts and Royalty Receipts, reaching $735 million. Additionally, the company reported net cash provided by operating act